pressug.com News 24 7
Related Articles
Ugandan pharmaceutical company Dei BioPharma has filed a patent application in the United States for a new Ebola vaccine platform designed to protect against multiple strains of the deadly virus, a development the company says could strengthen Africa’s ability to respond faster and more independently when outbreaks hit.
The filing, submitted to the U.S. Patent and Trademark Office, covers a next-generation mRNA vaccine developed by the company’s founder, Dr Matthias Magoola.
Unlike existing Ebola vaccines that are approved for only one strain, Dei BioPharma says its technology is designed to target several of the virus types most responsible for outbreaks in Africa, including Zaire, Sudan and Bundibugyo.
For Uganda, where Ebola outbreaks remain a recurring public health threat, that distinction matters. When Ebola breaks out, it rarely gives countries time to prepare.
Health workers are forced into emergency mode, communities face movement restrictions, treatment centres are set up under pressure, and governments scramble for supplies, funding and vaccines, often relying heavily on outside support.
That dependence has long exposed a difficult reality for many African countries: the diseases may begin here, but the vaccines and treatments are usually developed, owned and controlled elsewhere. Dei BioPharma’s latest move speaks directly to that gap.
“This is not only a scientific milestone,” Dr Magoola said in a statement announcing the filing.
“It is a step toward African technological self-determination in epidemic preparedness. Africa must not only receive vaccines during crises; Africa must help design, manufacture and deploy them.”
The company says the vaccine uses mRNA technology, the same broad scientific platform behind several modern vaccines, to train the body’s immune system to recognise and fight Ebola viruses.
Its approach is different because it is designed to target shared features found across several dangerous Ebola strains, rather than focusing on one specific type. That could prove especially significant for Uganda.
The country has experienced multiple outbreaks over the years, including Sudan virus and the Bundibugyo virus, strains for which no licensed vaccine currently exists. That gap has become more urgent after the World Health Organization recently declared the current Bundibugyo virus disease outbreak in Uganda and the Democratic Republic of Congo a Public Health Emergency of International Concern.
WHO says there is still no approved vaccine or targeted treatment for Bundibugyo virus disease. Existing vaccines such as ERVEBO are approved only for Zaire ebolavirus. For ordinary Ugandans, the implications go beyond science labs and patent filings. When Ebola spreads, everyday life changes quickly.
Schools can close. Markets slow down. Border movement tightens. Families become fearful of contact. Businesses in affected districts lose income. Hospitals stretch beyond capacity. Healthcare workers take on enormous risks.
A vaccine that can be produced regionally, and potentially tailored to the strains more common in East and Central Africa, could reduce response time during future outbreaks and lower dependence on international supply chains.
That matters in rural communities where delays often cost lives. It also matters economically. Uganda’s health emergencies often carry hidden financial consequences. Tourism drops. Trade slows.
Public funds are redirected to emergency response. Communities already living on tight margins face further disruption. A stronger domestic vaccine manufacturing sector could reduce some of that pressure over time while also positioning Uganda more competitively in a growing pharmaceutical market.
Dei BioPharma says the patent application includes 24 claims covering the vaccine’s design, production process, delivery systems and outbreak-use planning. The company says the vaccine is intended for emergency response, frontline health workers and occupational protection.
It is now preparing for Phase One human trials, the first stage of testing in volunteers to assess safety and determine dosage. The firm says it hopes to pursue a regulatory pathway that could support conditional approval within four to five years, depending on trial results and review timelines.
That remains a long road. Patent protection does not mean approval. Human trials are complex, expensive and heavily regulated. Manufacturing at scale also requires infrastructure, international partnerships and strong quality controls.
But even at this early stage, the filing carries symbolic and strategic weight. Uganda is not often seen as a centre of vaccine innovation.
For years, African governments have argued that the continent needs stronger research and manufacturing capacity, especially after Covid-19 exposed how vulnerable lower-income countries were when competing for vaccines on the global market.
Many African leaders have since pushed for more regional production to reduce reliance on imports and improve emergency readiness. Dei BioPharma says it is already engaging with global and regional health partners, including WHO, CEPI, Gavi and African ministries of health as it prepares for eventual deployment.
Related
, https://observer.ug/news/ugandan-firm-files-ebola-vaccine-patent/
